Non-Psychiatric Medications with: Neuropsychiatric Adverse Events (Email Lecture Series)

Physician’s Guide for Clinical Psychiatry’s Next Triweekly Email Lecture Series Announcement: 

In this email lecture series, we will discuss the neuropsychiatric adverse events from following non-psychiatric medications:

(1) Montelukast (Singulair): April  29

This chapter will discuss the most recent FDA boxed warning issued for montelukast, in the following sections:

  • Neuropsychiatric side effects reported with the use of Montelukast.
  • Mechanism Underlying Neuropsychiatric Side Effects.
  • Is History of Psychiatric Disorder a Risk Factor?
  • When to Avoid Montelukast Use?
  • Reserve Montelukast Use for which medical conditions?
  • Clinical Recommendations.
  • Do Neuropsychiatric Symptoms resolve on Montelukast Discontinuation?

(2) Steroids: May 01

This chapter will be discussed in the following sections:

  • What is the dose equivalency among steroids?
  • What doses of steroids are known for cause these psychiatric symptoms?
  • How long does it take from initiation of steroid to development of neuropsychiatric manifestations?
  • How long does it take for patient to recover?
  • How do you manage these neuropsychiatric symptoms?

(3) Interferon: May 04

This chapter will be discussed in the following sections:

  • Does prophylactic treatment with antidepressant prevent future episodes of depression?
  • Does type of Interferon (PEG Interferon a2a and 2b) affects this prophylactic SSRI response?
  • Which SSRI should be considered for prophylactic treatment?
  • Which risk factors are predictive variables of major depression episode during interferon treatment.

(4) Levetiracetam: May 06

This chapter will be discussed in the following sections:

  • Behavioral symptoms associated with Levetiracetam.
  • Risk factors.
  • Treatment options.

(5) Isotretinoin: May 08

This chapter will be discussed in the following sections:

  • Behavioral symptoms associated with Isotretinoin.
  • Clinical Recommendation.

(6) Fluoroquinolone: May 11

This chapter will be discussed in the following sections:

  • Serious central nervous system side effects.
  • Risk factors.
  • Clinical tips.

(7) Mefloquine: May 13

This chapter will be discussed in the following sections:

  • Neurological side effects
  • Psychiatric side effects
  • Clinical recommendations

For Detailed Access:

Subscribe to Physician’s Guide for Clinical Psychiatry:

  • Total chapters= 252 and counting.
  • Chapters and Sections are frequently updated.
  • Each chapter includes references: with either pdf article or pubmed link for each article.
  • Triweekly Email Clinical Summary: subscribers receive 3 emails/week.
  • Goal: is to have all important clinically relevant topics in one course.
  • Annual Subscription of $65/year: for continued access to course on an annual basis.

Related Articles